Compare Ascendis Pharma A/S (ASND) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs OneSpan Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while OneSpan Inc trades at $15.17 (market cap $561.84M). The key difference: Ascendis Pharma A/S is far larger — about 31.6× OneSpan Inc's market cap, and OneSpan Inc pays a 3.43% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | OSPN | |
|---|---|---|
Market Cap | $17.74B | $561.84M |
Sector | Health | Technology |
52-Week High | $277.18 | $16.32 |
52-Week Low | $163.32 | $10.15 |
Enterprise Value | $18.11B | $520.04M |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
OneSpan (OSPN) trades at $15.17, down slightly by 0.26% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 28.47% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights investor attention and the upcoming Q2 2026 earnings release on August 4, 2026, alongside strategic leadership appointments to accelerate growth.
The outlook remains positive given consistent earnings beats and high analyst buy ratings, though risks include negative cash flow trends and competitive pressures. Upside potential exists if the company maintains its earnings momentum, but investors should monitor cash flow improvements and execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
